Cingulate

Cingulate EBITDA per Employee

The EBITDA per Employee of Cingulate (CING) as of Nov 21, 2026 is -1.41 M USD. In the previous year, EBITDA per Employee was -1.04 M USD — a change of 34.80% (lower).

EBITDA per Employee

-1.41 MUSD

YoY

34.80%

Last updated:

EBITDA per Employee of Cingulate is 2025 -1.41 M USD. EBITDA per Employee of Cingulate was 2024 -1.04 M USD. It decreases by 34.80% lower compared to the previous year.

The Cingulate EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2019
-776,484.00 USD
Jan 1, 2020
-472,224.20 USD
Jan 1, 2021
-1.38 M USD
Jan 1, 2022
-1.17 M USD
Jan 1, 2023
-1.52 M USD
Jan 1, 2024
-1.04 M USD
Jan 1, 2025
-1.41 M USD
The Cingulate EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-1.41 MUSD+34.80%
-1.04 MUSD-31.28%
-1.52 MUSD+30.08%
-1.17 MUSD-15.37%
-1.38 MUSD+191.94%
-472,224.20USD-39.18%
-776,484.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cingulate Stock analysis

What does Cingulate do? Cingulate Inc is a US-based biopharmaceutical company headquartered in Kansas City, Kansas, that focuses on the development, manufacturing, and commercialization of pharmaceutical products. The firm utilizes its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles designed to improve the lives of patients suffering from commonly diagnosed conditions. The company specifically targets the treatment of attention deficit/hyperactivity disorder (ADHD) through its innovative approach to drug delivery. The firm is currently developing two lead product candidates, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). These drug candidates both contain three releases of an active pharmaceutical ingredient combined into one small tablet dosage form. By employing this technology, Cingulate Inc aims to provide effective treatment options for ADHD across three core patient segments: children aged 6-12, adolescents aged 13-17, and adults aged 18 and older. Cingulate is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cingulate stock

EBITDA per Employee of Cingulate is -1.41 M USD in 2025.

EBITDA per Employee of Cingulate changed from -1.04 M USD to -1.41 M USD, representing a 34.80% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Cingulate since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Cingulate historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Cingulate

All Key Metrics — Cingulate